Navigation Links
Merck Pays More Than $400 Million to Settle Federal, State Medicaid Fraud Investigation Sparked by Qui Tam Whistleblower Case Detailing Marketing Schemes for Vioxx(R), Zocor(R), Several Other Drugs
Date:2/7/2008

PHILADELPHIA, Feb. 7 /PRNewswire/ -- One of the world's largest drug manufacturers, Merck & Co., Inc. ("Merck"), has agreed to pay more than $400 million to the U.S., 49 states and the District of Columbia to settle qui tam whistleblower-led allegations that the pharmaceutical giant illegally defrauded Medicaid and other public healthcare programs across the U.S., according to a federal Settlement Agreement unsealed today. Merck employed four schemes to grab or maintain market share for drugs including Vioxx(R), Zocor(R), Cozaar(R), Fosamax(R), Maxalt(R), and Singulair(R), according to qui tam whistleblower lawyers Steven H. Cohen, Mark Kleiman and BethAnne Yeager, who represent the whistleblower, a former Merck district sales manager.

Capping a marathon, seven-plus-year investigation among federal and state authorities and the qui tam whistleblower's legal team, the Merck case presents several major legal milestones, according to Cohen, Kleiman and Yeager, including:

-- The first Government recovery from investigation into marketing of

Zocor and Vioxx;

-- The first fully-coordinated whistleblower-federal-state Medicaid fraud

investigation;

-- The first Medicaid fraud enforcement in which the States, led by

Nevada, tested an innovative -- and successful -- prosecution theory;

-- The first federal and state nominal price Medicaid fraud settlement;

and

-- The second largest civil False Claims Act ("FCA") recovery to federal

and state Medicaid programs.

Although Merck did not admit to wrongdoing, in addition to returning $400 million to taxpayers, the Whitehouse Station, New Jersey-based drug manufacturer has agreed to be bound by a Corporate Integrity Agreement, according to Cohen, who, along with Yeager is associated with the Whistleblower Action Network in Chicago.

"Our relator, a former Merck sales manager, blew the whistle on Merck which resulted in a nationwide investigation by federal and state prosecutors that returned hundreds of millions of taxpayer dollars to the Medicaid program," Cohen said.

"When we realized the extent of the fraud, we took the evidence straight to the Government. Taking on Merck required close coordination and cooperation between us and the state and federal prosecutors. This taskforce approach and unrelenting commitment won a huge victory for the taxpayers." Kleiman said.

"This landmark case exposed abuses of Medicaid's Best Price nominal price exception, and strengthened the Medicaid Rebate program to reduce the states' drug costs," Yeager said.

Aside from the huge settlement, the second largest FCA civil fraud Medicaid recovery, the case marked new ground with a collaborative investigation model that saw the relator and his lawyers work closely with state and federal Government investigators to press the case. This new investigative model, Cohen said, "will become the basis for future qui tam whistleblower investigations, especially in an age of shrinking government budgets."

The FCA, initially sponsored by President Abraham Lincoln to stop military fraud during the Civil War, allows private citizens with knowledge of fraud to help the Government recover ill-gotten gains and additional civil penalties. The FCA allows the Government to collect up to three times the amount it was defrauded, in addition to civil penalties of $5,500 to $11,000 per false claim. Whistleblowers whose cases settle or are won in court usually receive rewards representing 15 to 25 percent of qui tam recoveries.

The federal investigation was conducted by the U.S. Attorney's Office for the Eastern District of Pennsylvania, under the direction of Patrick L. Meehan, U.S. Attorney, Assistant U.S. Attorney Virginia Gibson, Chief of the Civil Division, and Assistant U.S. Attorney Viveca Parker. Parker led the broad investigation, including the review of more than 400 boxes of Merck documents, and fostered the coordinated work of her office, the states, the whistleblower and his attorneys.

At the state level, Nevada Chief Deputy Attorney General Tim Terry, head of the state's Medicaid Fraud Control Unit, worked with the whistleblower legal team on the groundbreaking companion case brought by the State of Nevada and the whistleblower. The Nevada case is part of the of the $400 million global settlement announced today.

Terry and Patrick Keenan, Deputy Attorney General for Illinois, along with representatives from Attorneys' General Offices in Delaware, Massachusetts and Illinois made up the investigation team on behalf of the States' Medicaid fraud units that brought about today's global settlement.

Cohen, Kleiman and Yeager praised the work of the investigation team. "The federal and state prosecutors on this case represent the highest calling of public service, Cohen said. "If it had not been for Tim Terry, Viveca Parker and the rest of the Government team we would not be announcing today's global settlement against Merck."

United States ex rel. Steinke, et al. v. Merck & Co., Inc., U.S. Dist. Ct. Case No. 00-CV-6158 (E.D. Pa.)

State of Nevada ex rel. Steinke v. Merck & Co., Inc., U.S. Dist. Ct. Case No. 3:05-cv-00322 HDM RAM (D. Nev.)

Attention Reporters: Visit and bookmark the precedent-setting original content Web reference developed for this case at http://www.drugfraudsettlement.com. The site provides an in-depth look at the fraud allegations, federal and state laws, and includes an extensive timeline with milestone dates/periods during the seven-year investigation. Also explained is the new model of cooperation among federal and state investigators, relator and qui tam whistleblower attorneys which promises to be the basis for future complex healthcare fraud qui tam investigations.


'/>"/>
SOURCE PRforLAW, LLC
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. CORRECTED: Hagens Berman Sobol Shapiro Files Suit Against Merck and Schering-Plough
2. Lawsuit Filed in Florida Federal Court Over Marketing of Vytorin and Zetia By Merck and Schering-Plough
3. BioMarin Re-Acquires Rights to Kuvan in Canada From Merck Serono
4. ICx Technologies Works With Merck & Co., Inc. to Develop Cancer Diagnostic Technology
5. GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc.
6. The Lanier Law Firm Announces $4.85 Billion National Vioxx Settlement With Merck & Co. Inc.
7. Dynavax and Merck & Co., Inc. Announce Partnership to Develop HEPLISAV(TM), an Investigational Hepatitis B Vaccine Currently in Phase 3
8. ImClone and Bristol-Myers Squibb Announce Joint Agreement With Merck KGaA to Co-Develop and Co-Commercialize ERBITUX(R) in Japan
9. AHF Challenges Merck Over Steep Price of Its New AIDS Drug, Isentress
10. Mylan Vice Chairman and CEO Robert J. Coury to Ring NYSE Closing Bell(R) in Celebration of Merck Generics Acquisition
11. Merck & Co., Inc. Response to Todays New York Medicaid Suit
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... ... 2017 , ... The 89th Academy Awards will be celebrated this weekend, which ... Center Bunkum Award. We invite you to enjoy our 11th annual tongue-in-cheek “salute” to ... the Center for American Progress (CAP), for its report, Lessons From State Performance on ...
(Date:2/23/2017)... ... February 23, 2017 , ... Rare Disease Report®, which is ... in Rare Disease Day events, hosted by the Rare Disease Legislative Advocates (RDLA) ... website, weekly e-newsletter and quarterly publication, will be conducting interviews with patients and ...
(Date:2/23/2017)... ... 2017 , ... Los Angeles-based weight loss surgeon Michael Feiz, M.D., F.AC.S. will ... to Hot,” which will begin airing on February 24, 2017. The show chronicles the ... 2012 reality television series, “Here Comes Honey Boo Boo.” The earlier series from TLC ...
(Date:2/23/2017)... ... 23, 2017 , ... Rosica Communications, a national PR ... media management, corporate communications, SEO and cause marketing, is opening an office in ... Hampshire, Massachusetts and Canada, Rosica will focus on expanding its footprint. , ...
(Date:2/23/2017)... Angeles, California (PRWEB) , ... February 23, 2017 ... ... Global Sports Development will host a diverse symposium on “Doping in ... of Law and Sheppard Mullin Richter & Hampton LLP. The symposium will be ...
Breaking Medicine News(10 mins):
(Date:2/24/2017)... , Feb 24, 2017 Research and ... Price Analysis and Strategies - 2016" report to their offering. ... The latest ... drug pricing data and benchmarks in the global Urinary Incontinence market. ... What are the key drugs marketed for Urinary Incontinence and ...
(Date:2/23/2017)... Research and Markets has announced the addition of the ... report to their offering. ... The latest research Autism Spectrum Disorder Drugs Price Analysis ... the global Autism Spectrum Disorder market. The research answers the ... drugs marketed for Autism Spectrum Disorder and their clinical attributes? How ...
(Date:2/23/2017)... , Südkorea, 23. Februar 2017 LG Innotek ... Sterilisationsaufgaben vorgestellt. Die Sterilisationsleistung beträgt das 1,5-fache des 45-mW-Moduls ... Strahlung im Bereich zwischen 200 und 280 nm und eignet ... Bakterien, indem es ihre DNA zerstört. Das Produkt von ... ...
Breaking Medicine Technology: